Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Operating Leases (2021 - 2025)

Historic Operating Leases for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $949000.0.

  • ARS Pharmaceuticals' Operating Leases changed N/A to $949000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $949000.0, marking a year-over-year change of. This contributed to the annual value of $37000.0 for FY2023, which is 8525.9% down from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Operating Leases stood at $949000.0.
  • Over the past 5 years, ARS Pharmaceuticals' Operating Leases peaked at $5.1 million during Q3 2021, and registered a low of $37000.0 during Q4 2023.
  • Over the past 4 years, ARS Pharmaceuticals' median Operating Leases value was $949000.0 (recorded in 2025), while the average stood at $1.7 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Operating Leases skyrocketed by 12862.77% in 2022, and later plummeted by 9640.84% in 2023.
  • Over the past 4 years, ARS Pharmaceuticals' Operating Leases (Quarter) stood at $480000.0 in 2021, then tumbled by 47.71% to $251000.0 in 2022, then crashed by 85.26% to $37000.0 in 2023, then soared by 2464.86% to $949000.0 in 2025.
  • Its last three reported values are $949000.0 in Q3 2025, $1.1 million for Q2 2025, and $37000.0 during Q4 2023.